1,230 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Carl P. Sherr & Co. LLC

Carl P. Sherr & Co. LLC bought a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 1,230 shares of the pharmaceutical company’s stock, valued at approximately $643,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth approximately $11,975,849,000. Bank of America Corp DE acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $1,509,651,000. Legal & General Group Plc acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $928,893,000. Bank of New York Mellon Corp bought a new position in Vertex Pharmaceuticals during the second quarter worth $830,842,000. Finally, Deutsche Bank AG bought a new position in Vertex Pharmaceuticals during the second quarter worth $784,391,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Down 0.7%

Shares of Vertex Pharmaceuticals stock opened at $538.60 on Friday. The business has a fifty day simple moving average of $522.37 and a 200-day simple moving average of $483.84. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $412.27 and a fifty-two week high of $568.67. The firm has a market cap of $136.56 billion, a price-to-earnings ratio of 34.66, a price-to-earnings-growth ratio of 2.87 and a beta of 0.28. The company has a quick ratio of 1.89, a current ratio of 2.34 and a debt-to-equity ratio of 0.17.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The company had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The company’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the prior year, the business posted $4.80 EPS. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on VRTX. Cantor Fitzgerald increased their target price on shares of Vertex Pharmaceuticals from $595.00 to $619.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. UBS Group lifted their price target on shares of Vertex Pharmaceuticals from $615.00 to $640.00 and gave the company a “buy” rating in a report on Tuesday, November 3rd. Scotiabank boosted their price objective on shares of Vertex Pharmaceuticals from $558.00 to $660.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 3rd. Daiwa Securities Group increased their price objective on shares of Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Truist Financial raised their target price on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $596.44.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.